High Incidence of Bloodstream Infection Due to Gram-negative Bacilli in Patients With Pulmonary Hypertension Receiving Intravenous Treprostinil
| Autor: | Elvira Barrios, Maria J. Ruiz-Cano, Pilar Escribano, María Vicente-Hernández, Mario Fernández-Ruiz, José María Aguado, Francisco López-Medrano |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty Hypertension Pulmonary Bacteremia Cohort Studies Sepsis Internal medicine Gram-Negative Bacteria medicine Humans Familial Primary Pulmonary Hypertension Infusions Intravenous Antihypertensive Agents Retrospective Studies Univariate analysis business.industry Incidence Incidence (epidemiology) Hazard ratio Retrospective cohort study General Medicine Middle Aged medicine.disease Epoprostenol Pulmonary hypertension Anesthesia Female business Treprostinil medicine.drug |
| Zdroj: | Archivos de Bronconeumología (English Edition). 48:443-447 |
| ISSN: | 1579-2129 |
| DOI: | 10.1016/j.arbr.2012.09.008 |
| Popis: | Introduction: An excessive risk for bacteremia has recently been reported in patients with pulmonary arterial hypertension (PAH) treated with intravenous treprostinil. We aimed to assess this association in a cohort of patients from a Spanish referral center. Patients and methods: We performed a retrospective cohort study that included 55 patients diagnosed with PAH who received a continuous intravenous infusion of a prostanoid (epoprostenol or treprostinil) for ≥ 1. month at our center between January 1991 and December 2011. The risk factors associated with the incidence of bacteremia were analyzed with the log-rank test. Results: After a total follow-up of 64,453 treatment days, we found 12 episodes of bacteremia: Staphylococcus aureus (5 episodes), non-fermenting gram-negative bacilli (4 episodes), other gram-positive cocci (2 episodes), and Enterobacter cloacae (one episode). The incidence of bacteremia was 0.118 episodes per 1,000 treatment days in patients receiving epoprostenol versus 0.938 episodes per 1,000 treatment-days in patients receiving treprostinil (P=0037). All episodes of bacteremia due to Gram-negative bacilli were diagnosed in patients on treprostinil. In the univariate analysis the treatment with intravenous treprostinil was associated with the incidence of bacteremia (hazard ratio: 4.09; 95% confidence interval: 1.24-14.53), although the low number of events prevented us from performing a multivariate analysis. Conclusions: Therapy with intravenous treprostinil is associated with a higher risk for bacteremia, especially due to non-fermenting Gram-negative bacilli. This association should be taken in consideration when choosing empirical antibiotic therapy for patients with PAH and sepsis. © 2012 SEPAR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect